CAR-T therapy dilemma and innovative design strategies for next generation
Open Access
- 27 March 2025
- journal article
- review article
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
Abstract
Chimeric antigen receptor (CAR)-T-cell therapy has shown remarkable curative effects on hematological tumors, driving the exponential growth in CAR-T-related research. Although CD19-targeting CAR-T-cell therapy has displayed remarkable promise in clinical trials, many obstacles are arising that limit its therapeutic efficacy in tumor immunotherapy. The “dilemma” of CAR-T cell-based tumor therapy includes lethal cytotoxicity, restricted trafficking, limited tumor infiltration, an immunosuppressive microenvironment, immune resistance and limited potency. The solution to CAR-T-cell therapy’s dilemma requires interdisciplinary strategies, including synthetic biology-based ON/OFF switch, bioinstructive scaffolds, nanomaterials, oncolytic viruses, CRISPR screening, intestinal microbiota and its metabolites. In this review, we will introduce and summarize these interdisciplinary-based innovative technologies for the next generation CAR-T-cell design and delivery to overcome the key barriers of current CAR-T cells.Keywords
This publication has 117 references indexed in Scilit:
- Inosine induces stemness features in CAR-T cells and enhances potencyCancer Cell, 2024
- CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacyCancer Immunology, Immunotherapy, 2022
- CXCR6-based immunotherapy in autoimmune, cancer and inflammatory inflictionActa Pharmaceutica Sinica B, 2022
- CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironmentCell, 2021
- In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisionsCell, 2021
- Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor modelsCancer Immunology, Immunotherapy, 2021
- CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinomaEuropean Journal of Immunology, 2020
- Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironmentScience China Life Sciences, 2019
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T CellsCell, 2019
- Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapiesBiomaterials, 2016